Bonnee Binker and Paul Motenko to lead efforts in Washington, D.C., for volunteer conference, teamMATEs: Together Until It's Done.
Site Search
The U.S. Food and Drug Administration (FDA) approved the use of ivacaftor (Kalydeco®) today for people ages 2 and older with cystic fibrosis who have at least one of the following five splice mutations: 3849+10kbC->T, 2789+5G->A, 3272-26A->G, 711+3A->G, E831X.
The U.S. Food and Drug Administration (FDA) today approved ivacaftor (Kalydeco®) for people ages 2 and older who have at least one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
On April 7, the Foundation presented the Alex, Jena, and Dream Big Awards to leaders in the cystic fibrosis community for their dedication to the Foundation's mission of finding a cure.
The Cystic Fibrosis Foundation announced the recipients of its sixth annual Impact Grants.
To date, the CF Foundation has funded more than $1 million to programs created by and for the CF community.
As a volunteer, you’ll join thousands of people across the country who are helping add tomorrows to the lives of people with cystic fibrosis.